Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Statins: Are they really all the same?

Author(s): Francesca Cortese

Volume 17, Issue 3, 2019

Page: [211 - 212] Pages: 2

DOI: 10.2174/1570161116666180713120217

« Previous Next »
[1]
Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30(12): 2311-6.
[2]
Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 2015; 132(17): 1667-78.
[3]
Catapano AL, Graham I, De Backer G, et al. Authors/task force members; additional contributor. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37(39): 2999-58.
[4]
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2014; 129(25)(Suppl. 2): 1-45.
[5]
Tiwari V, Khokhar M. Mechanism of action of anti-hypercholesterolemia drugs and their resistance. Eur J Pharmacol 2014; 741: 156-70.
[6]
Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010; 35: 139-51.
[7]
Chasman D, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: The Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 2012; 5: 257-64.
[8]
Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis 2014; 24: 1057-66.
[9]
Genser B, Marz W. Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. Clin Res Cardiol 2006; 95: 393-4.
[10]
Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011; 104: 109-24.
[11]
Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010; 170: 1024-31.
[12]
Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816.
[13]
Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946-52.
[14]
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
[15]
Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295(13): 1556-65.
[16]
Gao WQ, Feng QZ. Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. BMC Cardiovasc Disord 2014; 14: 60.
[17]
Cortese F, Gesualdo M, Cortese A, et al. Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacol Res 2016; 107: 1-18.
[18]
Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circulation J 2010; 74: 818-26.
[19]
McGuinness B, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev 2014; 7: CD007514.
[20]
Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2013; 12: CD008623.
[21]
Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367: 1792-02.
[22]
Li L, Sun T, Zhang P, Tian J, Yang K. Statins for primary prevention of venous thromboembolism. Cochrane Database Syst Rev 2011; 12: CD008203.
[23]
Raval AD, Hunter T, Stuckey B, Hart RJ. Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev 2011; 10: CD008565.
[24]
Toth PP, Worthy G, Gandra SR, et al. Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia. J Am Heart Assoc 2017; 6: e005367.

Rights & Permissions Print Cite
Article Metrics
55
3
1
1
© 2024 Bentham Science Publishers | Privacy Policy